June 6, 2011

New Data in Breast and Ovarian Cancer Presented at ASCO Support Continued Development of Iniparib

 

New Data in Breast and Ovarian Cancer Presented at ASCO Support Continued Development of Iniparib

Paris, France – June 6, 2011 – Sanofi (EURONEXT: SAN and NYSE: SNY) today announced new data for iniparib (BSI-201), an investigational agent, in metastatic triple-negative breast cancer (mTNBC), platinum-sensitive and platinum-resistant recurrent ovarian cancer. The data were presented at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.